Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jul 26;7(8):591-593.
doi: 10.1002/jgh3.12938. eCollection 2023 Aug.

Drug-induced liver injury by glatiramer acetate leading to liver transplant: A case report

Nikan Amirkhani  1 , Amirmohammad Khalaji  1   2 , Parsa Alehossein  1   3 , Masoomeh Safaei  4 , Najme Aletaha  5 , Arash Miroliaee  5
Affiliations
Case Reports

Drug-induced liver injury by glatiramer acetate leading to liver transplant: A case report

Nikan Amirkhani et al. JGH Open. .

Abstract

Glatiramer acetate (GA) is a widely used immune-modulating drug in relapsing multiple sclerosis (MS). Although a few cases of drug-induced liver injury during GA therapy have been reported earlier, herein we present the case of a 43-year-old woman with relapsing MS who experienced acute liver failure after GA therapy, ultimately leading to liver transplant.

Keywords: drug‐induced liver injury; glatiramer acetate; liver failure; liver transplantation; multiple sclerosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Axial view of abdominal computed tomography scan; (b, c) HE‐stained slides from the whole‐organ excised liver.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372: 1502–1517. - PubMed
    1. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N. Engl. J. Med. 2018; 378: 169–180. - PMC - PubMed
    1. Montalban X, Gold R, Thompson AJ et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler. 2018; 24: 96–120. - PubMed
    1. Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease‐modifying therapies in patients with relapsing‐remitting multiple sclerosis: a systematic review and network meta‐analysis. J. Neurol. 2020; 267: 3489–3498. - PubMed
    1. Signori A, Gallo F, Bovis F, Di Tullio N, Maietta I, Sormani MP. Long‐term impact of interferon or Glatiramer acetate in multiple sclerosis: a systematic review and meta‐analysis. Mult. Scler. Relat. Disord. 2016; 6: 57–63. - PubMed

Publication types